Avance Clinical and Julius Clinical Forge Global Partnership to Accelerate Biotech Trials

Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Juli...

May 31, 2024 | Friday | News
European Commission Approves Opdivo® Combination Therapy for First-Line Treatment of Metastatic Urothelial Carcinoma

Bristol Myers Squibb  announced that the European Commission (EC) has approved Opdivo®(nivolumab) in combination with cisplatin and gemcitabine ...

May 30, 2024 | Thursday | News
AstraZeneca's TROPION-Lung01 Trial Reveals Datopotamab Delxtecan's Potential as New Treatment Option for Advanced Lung Cancer

TROPION-Lung01 Phase III trial had a local progressive or metastatic non-small cell lung cancer with at least one treatment history in the past ( Datopot...

May 29, 2024 | Wednesday | News
Novartis' Atrasentan Demonstrates Significant Reduction in Proteinuria, Offering Hope for Improved Management of IgA Nephropathy

  The ALIGN study, focusing on atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, revealed a remarkable 36.1% redu...

May 27, 2024 | Monday | News
YGION Biomedical Secures €15M in Series A Funding to Advance Personalized Cancer Vaccine Technology

YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A fina...

May 21, 2024 | Tuesday | News
Telix's TLX592 Shows Promise in Prostate Cancer Treatment, Advances to Phase I/II Study

CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer. Establ...

May 14, 2024 | Tuesday | News
Recce Pharmaceuticals Initiates Phase I/II Trial with RECCE® 327, Administering Record Dosage for Urinary Tract Infections

First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future - 4,000mg highest dosage to dat...

May 20, 2024 | Monday | News
InnoCare Pharma Completes Patient Enrollment for Phase II Trial of ICP-488, Advancing Novel Psoriasis Treatment

InnoCare Pharma,  a leading biopharmaceutical company dedicated to revolutionizing the treatment of cancer and autoimmune diseases, proudly announces ...

May 16, 2024 | Thursday | News
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

Genentech, a member of the Roche Group  announced positive results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being...

May 16, 2024 | Thursday | News
HUTCHMED Initiates Registrational Phase III Clinical Trial of HMPL-306 for Relapsed / Refractory Acute Myeloid Leukemia in China

  AML, a challenging hematological malignancy, often involves mutations of IDH1 and IDH2 enzymes, necessitating innovative treatment strategies. HMPL...

May 14, 2024 | Tuesday | News
CytomX Therapeutics Collaborates with MSD for First-in-Human Trial of Novel CX-801 Cytokine to Revolutionize Cancer Treatment

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-i...

May 08, 2024 | Wednesday | News
Innovent Biologics Receives Breakthrough Therapy Designation for IBI343 in Advanced Gastric Cancer Treatment

Innovent Biologics a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncol...

May 07, 2024 | Tuesday | News
High Response Rate in Marginal Zone Lymphoma Patients: Initial Data Shows ZYNLONTA® Efficacy

Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient ach...

May 06, 2024 | Monday | News
Walgreens and Boehringer Ingelheim Forge Strategic Partnership to Democratize Clinical Trials

Walgreens and Boehringer Ingelheim announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusiv...

May 03, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close